Dymista (azelastine and fluticasone) nasal spray approved in Europe
Source: BioSpace
Area: News
Dymista (azelastine and fluticasone) nasal spray has been approved in Europe for the treatment of seasonal and perennial allergic rhinitis.. Efficacy and safety have been evaluated in several studies with over 4000 patients, including a long-term safety study with more than 600 patients. Launches are anticipated in 2013 in several countries. (Source: NeLM - News)
Source: NeLM - News - January 25, 2013 Category: Drugs & Pharmacology Source Type: news
FDA Updates Lopinavir/Ritonavir (Kaletra) Labeling to Include New Drug Interaction Information
"On January 17, 2013, FDA approved revisions to the Kaletra (lopinavir/ritonavir) labels to include new drug interaction information. The following updates were included.
"Anticoagulants: Rivaroxaban. Avoid concomitant use of rivaroxaban and Kaletra. Coadministration of Kaletra and rivaroxaban is expected to result in increased exposure of rivaroxaban which may led to risk of increased bleeding
"Anticonvulsants: Lamotrigine and valproate. Coadministration of Kaletra and lamotrigine or valproate may decrease the exposure of lamotrigine or valproate. A dose increase of the lamotrigine or valproate may be nee...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 22, 2013 Category: Infectious Diseases Source Type: news
Is children's asthma made worse by inhalers?
Conclusion
This proof-of-concept trial suggests that montelukast offers a more effective treatment option than salmeterol in a group of children with poorly controlled asthma and a specific genetic variation.
The researchers concluded that “adding montelukast to inhaled fluticasone significantly reduced school absences, improved asthma symptoms and quality-of-life, while reducing inhaled reliever use” compared to salmeterol. They also say that “the relative benefits of montelukast in comparison to salmeterol became evident within the first three months and persisted throughout the whole year.” They suggest that th...
Source: NHS News Feed - January 8, 2013 Category: Consumer Health News Tags: Heart/lungs Pregnancy/child Source Type: news
MHRA consults on reclassification of Pirinase Hayfever Relief for Adults 0.05% Nasal Spray (fluticasone propionate) from P to GSL
Source: MHRA
Area: News
Consultation ARM 83 seeks views on the reclassification of Pirinase Hayfever Relief for Adults 0.05% Nasal Spray (fluticasone propionate) from Pharmacy (P) to General Sales List (GSL). The Reclassification Summary and patient information leaflet as provided by the applicant company are available via the link below.
The closing date for receipt of comments is 1 Feb 2013. (Source: NeLM - News)
Source: NeLM - News - January 8, 2013 Category: Drugs & Pharmacology Source Type: news
Flutiform (fluticasone proprionate and formoterol fumarate) for Treatment of Asthma
Flutiform (fluticasone proprionate and formoterol fumarate) is a combination therapy used for the treatment of asthma. (Source: Drug Development Technology)
Source: Drug Development Technology - January 3, 2013 Category: Pharmaceuticals Source Type: news
